PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
BridgeBio Oncology Therapeutics, Inc. (BBOT) said the U.S. Food and Drug Administration has granted Fast Track designation to BBO-11818 for the treatment of adults with advanced KRAS-mutant pancreatic ductal adenocarcinoma. The designation follows preliminary data released in January 2026, in which...
A new study shows that as more people use electric bikes and scooters, serious head and spine injuries are increasing among both riders and pedestrians in cities. The lead researcher, Hannah Weiss, a neurosurgery doctor in training, said she was shocked by how many patients were coming in with these...
A 2023 review explored whether the length of time poop stays in the body before being passed affects the gut bacteria. They looked at earlier studies involving thousands of people, including both healthy individuals and those with conditions like irritable bowel syndrome, constipation, and liver disease....
Immuneering Corporation (IMRX), a late-stage clinical oncology company, on Monday presented promising genetic data from clinical trials of cancer drug Atebimetinib at the annual meeting of the American Association of Cancer Research (AACR). Atebimetinib is a Deep Cyclic inhibitor of MEK, a pathway...